---
title: "Cobicistat - Human Immunodeficiency Virus Infection - 2"
sidebar: mydoc_sidebar
permalink: db09065-mesh-d015658-2.html
toc: false 
---


Path ID: `DB09065_MESH_D015658_2`
{% include image.html url="images/db09065-mesh-d015658-2.png" file="db09065-mesh-d015658-2.png" alt="db09065-mesh-d015658-2" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D000069547 | cobicistat | Drug |
| InterPro:IPR001128ï»¿ | Cytochrome P450 | GeneFamily |
| GO:0042178 | xenobiotic catabolic process | BiologicalProcess |
| CHEBI:22587 | antiviral agent | ChemicalSubstance |
| MESH:D015658 | Human immunodeficiency virus infection | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Cobicistat | NEGATIVELY REGULATES | Cytochrome P450 |
| Cytochrome P450 | POSITIVELY REGULATES | Xenobiotic Catabolic Process |
| Xenobiotic Catabolic Process | DECREASES ABUNDANCE OF | Antiviral Agent |
| Antiviral Agent | NEGATIVELY CORRELATED WITH | Human Immunodeficiency Virus Infection |
|---------|-----------|---------|

Comment: Cobicistat does not have any anti-HIV activity on its own; it acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes (https://pubchem.ncbi.nlm.nih.gov/compound/25151504#section=Mechanism-of-Action)

Reference: 
  - [https://go.drugbank.com/drugs/DB09065](https://go.drugbank.com/drugs/DB09065)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2095208/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2095208/)
